The presentation will be webcast live and may be accessed by visiting Daré's website at http://ir.darebioscience.com. A replay of the webcast will be available for 10 business days.
About Daré Bioscience
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women's reproductive health. Daré believes there is an unmet global need in women's reproductive health for new products that expand options, improve outcomes and are easy to use. Product development in women's reproductive health is fragmented creating a potential opportunity for Daré. The Company seeks to fill this gap by taking promising product candidates through clinical development and believes the team is well suited to ensure current and potential future product candidates advance and one day become commercially available to women worldwide. Daré's executive management team brings experience in global women's healthcare as well as a track record of success in prior ventures in financing, partnering, commercializing, and achieving regulatory approval for medical devices, therapeutics and diagnostics. For more information on Daré, please visit www.darebioscience.com.
This press release contains "forward-looking statements"
within the meaning of The Private Securities Litigation Reform Act of 1995 regarding matters that are not historical facts, including statements relating to Daré's expectations regarding the anticipated market demands for its products, the safety and effectiveness of its products, market acceptance of Dare's products and the qualifications and expertise of Dare's management team. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and completion of clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that trial or
whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals; claims of infringement and other risks relating to Daré's owned and licensed intellectual property rights, and other factors discussed in the "Risk Factors" section of Daré's Quarterly Report on Form 10-Q filed with the
Source: Daré Bioscience
News Provided by Acquire Media